Re-purposing cryoablation

A combinatorial 'therapy' for the destruction of tissue

J. G. Baust, John C Bischof, S. Jiang-Hughes, T. J. Polascik, D. B. Rukstalis, A. A. Gage, J. M. Baust

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

It is now recognized that the tumor microenvironment creates a protective neo-tissue that isolates the tumor from the various defense strategies of the body. Evidence demonstrates that, with successive therapeutic attempts, cancer cells acquire resistance to individual treatment modalities. For example, exposure to cytotoxic drugs results in the survival of approximately 20-30% of the cancer cells as only dividing cells succumb to each toxic exposure. With follow-up treatments, each additional dose results in tumor-associated fibroblasts secreting surface-protective proteins, which enhance cancer cell resistance. Similar outcomes are reported following radiotherapy. These defensive strategies are indicative of evolved capabilities of cancer to assure successful tumor growth through well-established anti-tumor-protective adaptations. As such, successful cancer management requires the activation of multiple cellular 'kill switches' to prevent initiation of diverse protective adaptations. Thermal therapies are unique treatment modalities typically applied as monotherapies (without repetition) thereby denying cancer cells the opportunity to express defensive mutations. Further, the destructive mechanisms of action involved with cryoablation (CA) include both physical and molecular insults resulting in the disruption of multiple defensive strategies that are not cell cycle dependent and adds a damaging structural (physical) element. This review discusses the application and clinical outcomes of CA with an emphasis on the mechanisms of cell death induced by structural, metabolic, vascular and immune processes. The induction of diverse cell death cascades, resulting in the activation of apoptosis and necrosis, allows CA to be characterized as a combinatorial treatment modality. Our understanding of these mechanisms now supports adjunctive therapies that can augment cell death pathways.

Original languageEnglish (US)
Pages (from-to)87-95
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume18
Issue number2
DOIs
StatePublished - Jun 14 2015

Fingerprint

Cryosurgery
Cell- and Tissue-Based Therapy
Neoplasms
Cell Death
Therapeutics
Tumor Microenvironment
Poisons
Blood Vessels
Cell Cycle
Membrane Proteins
Necrosis
Radiotherapy
Hot Temperature
Apoptosis
Mutation

Cite this

Baust, J. G., Bischof, J. C., Jiang-Hughes, S., Polascik, T. J., Rukstalis, D. B., Gage, A. A., & Baust, J. M. (2015). Re-purposing cryoablation: A combinatorial 'therapy' for the destruction of tissue. Prostate Cancer and Prostatic Diseases, 18(2), 87-95. https://doi.org/10.1038/pcan.2014.54

Re-purposing cryoablation : A combinatorial 'therapy' for the destruction of tissue. / Baust, J. G.; Bischof, John C; Jiang-Hughes, S.; Polascik, T. J.; Rukstalis, D. B.; Gage, A. A.; Baust, J. M.

In: Prostate Cancer and Prostatic Diseases, Vol. 18, No. 2, 14.06.2015, p. 87-95.

Research output: Contribution to journalReview article

Baust, JG, Bischof, JC, Jiang-Hughes, S, Polascik, TJ, Rukstalis, DB, Gage, AA & Baust, JM 2015, 'Re-purposing cryoablation: A combinatorial 'therapy' for the destruction of tissue', Prostate Cancer and Prostatic Diseases, vol. 18, no. 2, pp. 87-95. https://doi.org/10.1038/pcan.2014.54
Baust, J. G. ; Bischof, John C ; Jiang-Hughes, S. ; Polascik, T. J. ; Rukstalis, D. B. ; Gage, A. A. ; Baust, J. M. / Re-purposing cryoablation : A combinatorial 'therapy' for the destruction of tissue. In: Prostate Cancer and Prostatic Diseases. 2015 ; Vol. 18, No. 2. pp. 87-95.
@article{51c2429913a2409e97070775193106ad,
title = "Re-purposing cryoablation: A combinatorial 'therapy' for the destruction of tissue",
abstract = "It is now recognized that the tumor microenvironment creates a protective neo-tissue that isolates the tumor from the various defense strategies of the body. Evidence demonstrates that, with successive therapeutic attempts, cancer cells acquire resistance to individual treatment modalities. For example, exposure to cytotoxic drugs results in the survival of approximately 20-30{\%} of the cancer cells as only dividing cells succumb to each toxic exposure. With follow-up treatments, each additional dose results in tumor-associated fibroblasts secreting surface-protective proteins, which enhance cancer cell resistance. Similar outcomes are reported following radiotherapy. These defensive strategies are indicative of evolved capabilities of cancer to assure successful tumor growth through well-established anti-tumor-protective adaptations. As such, successful cancer management requires the activation of multiple cellular 'kill switches' to prevent initiation of diverse protective adaptations. Thermal therapies are unique treatment modalities typically applied as monotherapies (without repetition) thereby denying cancer cells the opportunity to express defensive mutations. Further, the destructive mechanisms of action involved with cryoablation (CA) include both physical and molecular insults resulting in the disruption of multiple defensive strategies that are not cell cycle dependent and adds a damaging structural (physical) element. This review discusses the application and clinical outcomes of CA with an emphasis on the mechanisms of cell death induced by structural, metabolic, vascular and immune processes. The induction of diverse cell death cascades, resulting in the activation of apoptosis and necrosis, allows CA to be characterized as a combinatorial treatment modality. Our understanding of these mechanisms now supports adjunctive therapies that can augment cell death pathways.",
author = "Baust, {J. G.} and Bischof, {John C} and S. Jiang-Hughes and Polascik, {T. J.} and Rukstalis, {D. B.} and Gage, {A. A.} and Baust, {J. M.}",
year = "2015",
month = "6",
day = "14",
doi = "10.1038/pcan.2014.54",
language = "English (US)",
volume = "18",
pages = "87--95",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Re-purposing cryoablation

T2 - A combinatorial 'therapy' for the destruction of tissue

AU - Baust, J. G.

AU - Bischof, John C

AU - Jiang-Hughes, S.

AU - Polascik, T. J.

AU - Rukstalis, D. B.

AU - Gage, A. A.

AU - Baust, J. M.

PY - 2015/6/14

Y1 - 2015/6/14

N2 - It is now recognized that the tumor microenvironment creates a protective neo-tissue that isolates the tumor from the various defense strategies of the body. Evidence demonstrates that, with successive therapeutic attempts, cancer cells acquire resistance to individual treatment modalities. For example, exposure to cytotoxic drugs results in the survival of approximately 20-30% of the cancer cells as only dividing cells succumb to each toxic exposure. With follow-up treatments, each additional dose results in tumor-associated fibroblasts secreting surface-protective proteins, which enhance cancer cell resistance. Similar outcomes are reported following radiotherapy. These defensive strategies are indicative of evolved capabilities of cancer to assure successful tumor growth through well-established anti-tumor-protective adaptations. As such, successful cancer management requires the activation of multiple cellular 'kill switches' to prevent initiation of diverse protective adaptations. Thermal therapies are unique treatment modalities typically applied as monotherapies (without repetition) thereby denying cancer cells the opportunity to express defensive mutations. Further, the destructive mechanisms of action involved with cryoablation (CA) include both physical and molecular insults resulting in the disruption of multiple defensive strategies that are not cell cycle dependent and adds a damaging structural (physical) element. This review discusses the application and clinical outcomes of CA with an emphasis on the mechanisms of cell death induced by structural, metabolic, vascular and immune processes. The induction of diverse cell death cascades, resulting in the activation of apoptosis and necrosis, allows CA to be characterized as a combinatorial treatment modality. Our understanding of these mechanisms now supports adjunctive therapies that can augment cell death pathways.

AB - It is now recognized that the tumor microenvironment creates a protective neo-tissue that isolates the tumor from the various defense strategies of the body. Evidence demonstrates that, with successive therapeutic attempts, cancer cells acquire resistance to individual treatment modalities. For example, exposure to cytotoxic drugs results in the survival of approximately 20-30% of the cancer cells as only dividing cells succumb to each toxic exposure. With follow-up treatments, each additional dose results in tumor-associated fibroblasts secreting surface-protective proteins, which enhance cancer cell resistance. Similar outcomes are reported following radiotherapy. These defensive strategies are indicative of evolved capabilities of cancer to assure successful tumor growth through well-established anti-tumor-protective adaptations. As such, successful cancer management requires the activation of multiple cellular 'kill switches' to prevent initiation of diverse protective adaptations. Thermal therapies are unique treatment modalities typically applied as monotherapies (without repetition) thereby denying cancer cells the opportunity to express defensive mutations. Further, the destructive mechanisms of action involved with cryoablation (CA) include both physical and molecular insults resulting in the disruption of multiple defensive strategies that are not cell cycle dependent and adds a damaging structural (physical) element. This review discusses the application and clinical outcomes of CA with an emphasis on the mechanisms of cell death induced by structural, metabolic, vascular and immune processes. The induction of diverse cell death cascades, resulting in the activation of apoptosis and necrosis, allows CA to be characterized as a combinatorial treatment modality. Our understanding of these mechanisms now supports adjunctive therapies that can augment cell death pathways.

UR - http://www.scopus.com/inward/record.url?scp=84929267227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929267227&partnerID=8YFLogxK

U2 - 10.1038/pcan.2014.54

DO - 10.1038/pcan.2014.54

M3 - Review article

VL - 18

SP - 87

EP - 95

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -